Linking Atrial Fibrillation with Non-Alcoholic Fatty Liver Disease: Potential Common Therapeutic Targets

Ye Ding,Yuan Ma,Lin-Yan Qian,Qiang Xu,Lihong Wang,Dongsheng Huang,Hai Zou
DOI: https://doi.org/10.18632/oncotarget.19522
2017-01-01
Oncotarget
Abstract:Non-alcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF) are common chronic non-infectious diseases with rising incidences.NAFLD is an independent risk factor for the onset of AF, after adjusting potentially related factors.The pathogenesis of these diseases share several mechanisms including reduced adiponectin level, insulin resistance, and renin angiotensin aldosterone system (RAAS) activation, in addition to activation of common disease pathways that promote inflammation, oxidative stress, and fibrosis.Furthermore, statins and RAAS blockers exert therapeutic effects concurrently on NAFLD and AF.The common pathogenesis of NAFLD and AF may serve as a potential therapeutic target in the future.Oncotarget 60674 www.impactjournals.com/oncotargetRecent clinical investigations revealed a significant increasing in AF cases among patients with NAFLD, suggesting that NAFLD is an independent risk factor for AF [9][10][11][12][13].This article reviews the current literature about the epidemiology and mechanisms of NAFLD and AF, and discusses the relationship between the two conditions with the aim to provide new insights into the treatment of both NAFLD and AF.
What problem does this paper attempt to address?